Parthenolide: suggested drug for COVID-19

Cover Page

Cite item


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the 2019 novel coronavirus (2019-nCoV) that causes acute respiratory distress syndrome (ARDS) which is the main reason for patients mortality. One of the effective treatments to reduce the effects of this virus is parthenolide (PN). Parthenolide is a sesquiterpene lactone found in medicinal plants. It can inhibit several pro-inflammatory signaling pathways, in particular the ATPase activity of NLRP3. Based on its ability to suppress inflammatory signal transduction and elevated level of serum IL-1β (a surrogate marker for NLRP3 activation) in COVID-19 patients, we suggest that PN could be potentiallyeffective for the treatment of COVID-19.

About the authors

M. Nemati

Urmia University of Medical Sciences

ORCID iD: 0000-0002-4262-1636
Department of Biochemistry, School of Medicine.
Urmia Russian Federation

F. Danesh Pouya

Urmia University of Medical Sciences

ORCID iD: 0000-0002-2636-9856
Department of Biochemistry, School of Medicine.


Urmia Iran, Islamic Republic of

E. Roshani Asl

Urmia University of Medical Sciences

ORCID iD: 0000-0002-9783-5156
Department of Biochemistry, School of Medicine.


Urmia Iran, Islamic Republic of

Y. Rami

Urmia University of Medical Sciences

Author for correspondence.
ORCID iD: 0000-0003-1506-1909
Yousef Rasmi - Department of Biochemistry, School of Medicine, Urmia University MS; Cellular and Molecular Research Center, Urmia UMS.

Urmia, Phone: +989143174740, Fax: +984432780801

Iran, Islamic Republic of


  1. Abad M.J., Guerra J.A., Bermejo P., Govil J., Singh V.K., Mishra S.K. Phytochemistry and pharmacology of Tanacetum: recent developments (2008).
  2. Bauernfeind F.G., Horvath G., Stutz A., Alnemri E.S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B.G., Fitzgerald K.A., Hornung V., Latz E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol., 2009, vol. 183, no. 2, pp. 787—791. doi: 10.4049/jimmunol.0901363
  3. Dai Y., Guzman M.L., Chen S., Wang L., Yeung S.K., Pei X.Y., Dent P., Jordan C.T., Grant S. The NF (Nuclear factor)-KB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. Br. J. Haematol., 2010, vol. 151, no. 1, pp. 70—83. doi: 10.1111/j.1365-2141.2010.08319.x
  4. Dammann K., Khare V., Gasche C. Tracing PAKs from GI inflammation to cancer. Gut, 2014, vol. 63, no. 7, pp. 1173—1184. doi: 10.1136/gutjnl-2014-306768
  5. Fitzgerald K.N. A few additional treatment possibilities for COVID19 (SARS Cov-2) addressing furin-like cleavage and pyropto-sis (caspase-1 activation of inflammasome NLRP3). URL: (10.09.2020)
  6. Juliana C., Fernandes-Alnemri T., Wu J., Datta P., Solorzano L., Yu J.W., Meng R., Quong A.A., Latz E., Scott C.P., Alnemri E.S. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J. Biol. Chem., 2010, vol. 285, no. 13,pp. 9792-9802. doi: 10.1074/jbc.M109.082305
  7. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu. Rev. Immunol., 2009, vol. 27, pp. 229-265.
  8. Maruta H., He H. A mini-review for COVID-19 issue (2020). URL: (20.08.2020)
  9. Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med., 2020, vol. 46, no. 5, pp. 846-848. doi: 10.1007/s00134-020-05991-x
  10. Smolinski A.T., Pestka J.J. Comparative effects of the herbal constituent parthenolide (Feverfew) on lipopolysaccharide-induced inflammatory gene expression in murine spleen and liver. J. Inflamm., 2005, no. 2: 6. doi: 10.1186/1476-9255-2-6
  11. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet, 2020, vol. 395, no. 10223, pp. 470-473. doi: 10.1016/S0140-6736(20)30185-9

Copyright (c) 2020 Nemati M., Danesh Pouya F., Roshani Asl E., Rami Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies